Cardiology

Top Story

FDA approves ticagrelor for long-term use after ACS event

September 3, 2015

AstraZeneca announced that a 60 mg twice-daily dose of its antiplatelet agent ticagrelor has been approved by the FDA for prevention of CV death, MI and stroke in patients more than 1 year after an ACS event.

Ticagrelor (Brilinta) was previously approved in a 90 mg twice-daily dose for use in patients up to 1 year after an ACS event for prevention of CV events and stent thrombosis, according to an AstraZeneca press release.

Meeting News Coverage

Early, sensitive troponin I assessment safe, effective for acute MI diagnosis

September 3, 2015
LONDON — A new algorithm incorporating a more sensitive cutoff for troponin I values to identify non-STEMI would result in lower mortality and allow more rapid…
Pamela S. Douglas, MD Meeting News CoveragePerspective

PLATFORM: FFR-CT reduces unnecessary invasive catheterization in patients with suspected CAD

September 3, 2015
LONDON — Patients with suspected CAD planned for invasive catheterization were less likely to undergo an unnecessary procedure if their diagnosis was guided by CTA…
VIDEO: Five IMPROVE-IT analyses indicate safety, efficacy of ezetimibe Meeting News CoverageVideo

VIDEO: Five IMPROVE-IT analyses indicate safety, efficacy of ezetimibe

September 3, 2015
LONDON — In this video, Robert P. Giugliano, MD, a cardiologist at Brigham and Women's Hospital and senior investigator with the TIMI Study Group, discusses…
In the Journals

Calorie restriction could improve health outcomes related to aging

September 3, 2015
A 12% restriction in calories among average or slightly overweight individuals improved risk factors for age related diseases, as well as influenced blood pressure…
More News Headlines »
CME
Highlights from Lipid Forum 2015™: Focus on Hypertriglyceridemia

Highlights from Lipid Forum 2015®: Focus on Hypertriglyceridemia

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and…
More »
Meeting News Coverage Video
VIDEO: ARTS-HF results indicate benefits of finerenone for certain patients with HF

VIDEO: ARTS-HF results indicate benefits of finerenone for certain patients with HF

September 2, 2015
LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee…
More »
CME
Cardiology Case Consults

The Patient With Idiopathic Pulmonary Fibrosis

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with idiopathic pulmonary fibrosis.
More »
morganatic-roan